Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 23, 2024
Product Development
Amphista degrades a cancer target using a non-traditional ligase
Amphista’s targeted glues combine the advantages of PROTACs and molecular glues to create selective, orally bioavailable therapies
BioCentury | Mar 11, 2023
Discovery & Translation
NIBR’s IKZF2 molecular glue degrader; plus new optimized base editors and more
BioCentury’s roundup of translational news
BioCentury | Nov 11, 2022
Product Development
Molecular glue degraders: moving beyond IMiDs
Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases
BioCentury | Mar 12, 2022
Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
BioCentury | Oct 28, 2021
Product Development
Kymera adds to the clinical picture for protein degraders
The company digs into the biological effects of its IRAK4 degrader
BioCentury | Jun 29, 2021
Product Development
Surprised by targeted degrader’s single dose potency, Kymera broadens thinking on discovery platform
Company considering shorter term and more infrequent dosing for earlier stage programs
BioCentury | Mar 3, 2021
Product Development
With Kymera’s clinical debut, targeted protein degradation gets its first RCT
As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than
BioCentury | Feb 20, 2021
Product Development
BMS turns to mechanistic diversity in early oncology pipeline
BMS has holes to fill with upcoming patent expirations
BioCentury | Jan 5, 2021
Product Development
IRAK4 inhibitor pipeline: Data Byte
Several inflammatory and cancer indications will soon see human proof-of-concept data from small molecules targeting the kinase IRAK4, as a class of at least eight such molecules makes its way
Items per page:
1 - 10 of 21